Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc.（COLL）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · COLL · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
19
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Collegium Pharmaceutical, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
COLL 季度内部人买卖趋势
COLL 内幕交易卖出 · COLL 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · COLL CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
COLL 高管卖出股份 · COLL 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 18, 2026 | Freund John Gordon Director | Sale | 20 | $681 | Form 4 |
| May 14, 2026 | Lurker Nancy Director | Award | 8,741 | — | Form 4 |
| May 14, 2026 | Paya Carlos V Director | Award | 8,741 | — | Form 4 |
| May 15, 2026 | Freund John Gordon Director | Option | 8,700 | $143K | Form 4 |
| May 15, 2026 | Freund John Gordon Director | Sale | 4,127 | $143K | Form 4 |
| May 14, 2026 | Freund John Gordon Director | Award | 8,741 | — | Form 4 |
| May 14, 2026 | BOHLIN GAREN G Director | Award | 8,741 | — | Form 4 |
| May 14, 2026 | Glancy Donovan Michael Director | Award | 17,482 | — | Form 4 |
| May 14, 2026 | Balice-Gordon Rita J. Director | Award | 8,741 | — | Form 4 |
| May 14, 2026 | SANTINI GINO Director | Award | 8,741 | — | Form 4 |
| May 13, 2026 | Lurker Nancy Director | Sale | 4,500 | $162K | Form 4 |
| May 11, 2026 | BOHLIN GAREN G Director | Option | 8,700 | $143K | Form 4 |
| May 11, 2026 | BOHLIN GAREN G Director | Sale | 8,700 | $323K | Form 4 |
| Mar 17, 2026 | Dieter David EVP & General Counsel | Other | 8,840 | $316K | Form 4 |
| Mar 18, 2026 | Dieter David EVP & General Counsel | Sale | 13,976 | $488K | Form 4 |
| Mar 3, 2026 | Dreyer Scott EVP & Chief Commercial Officer | Sale | 46,417 | $1.87M⚡ | Form 4 |
| Mar 3, 2026 | Dreyer Scott EVP & Chief Commercial Officer | Sale | 3,559 | $146K | Form 4 |
| Feb 10, 2026 | Dieter David EVP & General Counsel | Award | 9,005 | — | Form 4 |
| Feb 10, 2026 | Dieter David EVP & General Counsel | Other | 2,781 | $130K | Form 4 |
| Feb 10, 2026 | Dieter David EVP & General Counsel | Award | 22,194 | — | Form 4 |
| Feb 10, 2026 | Karnani Vikram President and CEO · Director | Award | 32,531 | — | Form 4 |
| Feb 10, 2026 | Karnani Vikram President and CEO · Director | Other | 11,296 | $528K | Form 4 |
| Feb 10, 2026 | Karnani Vikram President and CEO · Director | Award | 79,264 | — | Form 4 |
| Feb 10, 2026 | Smith Thomas B EVP and Chief Medical Officer | Award | 22,774 | — | Form 4 |
| Feb 10, 2026 | Smith Thomas B EVP and Chief Medical Officer | Other | 5,897 | $276K | Form 4 |
Dreyer Scott
EVP & Chief Commercial Officer
日期
Mar 3
股数
46,417
均价
$40.36
总金额
$1.87M ⚡
Karnani Vikram
President and CEO · Director
日期
Feb 10
股数
11,296
均价
$46.75
总金额
$528K
Smith Thomas B
EVP and Chief Medical Officer
日期
Feb 10
股数
5,897
均价
$46.75
总金额
$276K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 COLL 内幕交易
COLL 内幕交易
Collegium Pharmaceutical, Inc.（COLL）内幕交易数据来源于公司内部人（包括Dreyer Scott (EVP & Chief Commercial Officer), Freund John Gordon (Director), Tupper Colleen (EVP & Chief Financial Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。COLL内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Collegium Pharmaceutical, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
COLL 内幕交易 · 5个问题Collegium Pharmaceutical, Inc.（COLL）的内部人包括高管和董事，如Dreyer Scott (EVP & Chief Commercial Officer), Freund John Gordon (Director), Tupper Colleen (EVP & Chief Financial Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026